2022
Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder
Lier A, Vander Wyk B, Di Paola A, Springer S. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. Open Forum Infectious Diseases 2022, 9: ofac624. PMID: 36467300, PMCID: PMC9709708, DOI: 10.1093/ofid/ofac624.Peer-Reviewed Original ResearchOpioid use disorderHepatitis C virusHCV treatment ratesHIV serostatusUse disordersHepatitis C virus (HCV) care cascadeHCV viral load testingTreatment ratesHCV treatment uptakeProspective cohort studyInjection drug useViral load testingGreater reductionDrug use frequencyHCV testingCare cascadeHCV antibodiesHIV screeningCohort studyHIV statusTreatment uptakeEntire cohortMedication treatmentC virusSerostatusFactors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addiction Science & Clinical Practice 2022, 17: 15. PMID: 35255967, PMCID: PMC8899775, DOI: 10.1186/s13722-022-00299-1.Peer-Reviewed Original ResearchConceptsOpioid use disorderHigher pain interferenceMOUD retentionPain interferenceUse disordersOngoing prospective cohort studySevere opioid use disorderProspective cohort studyMultivariable logistic regressionCohort of adultsMethadone doseAnalgesic effectBuprenorphine doseCohort studyOpioid useResultsA totalHigher oddsMOUDAdjusted modelHigh doseLogistic regressionBuprenorphineMethadoneDoseDiscontinuation
2021
Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence
Schultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, Springer SA. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. Contemporary Clinical Trials Communications 2021, 24: 100866. PMID: 34825103, PMCID: PMC8605182, DOI: 10.1016/j.conctc.2021.100866.Peer-Reviewed Original ResearchOpioid use disorderHIV-1 persistenceHIV persistenceCohort studyHIV infectionMedication treatmentLimited bloodUse disordersProviral landscapeDSM-5 opioid-use disordersExtended-release naltrexoneProspective cohort studyHIV-1 expressionPartial agonist buprenorphineLongitudinal studyHIV continuumMonth 3Clonal expansion dynamicsMOUDDifferential biological effectsStudy participantsHIVMolecular virologyBloodBuprenorphineDesign and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder
Biondi BE, Mohanty S, Vander Wyk BV, Montgomery RR, Shaw AC, Springer SA. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemporary Clinical Trials Communications 2021, 21: 100704. PMID: 33490708, PMCID: PMC7807244, DOI: 10.1016/j.conctc.2021.100704.Peer-Reviewed Original ResearchOpioid use disorderProspective cohort studyHIV infectionCohort studyMedication treatmentUse disordersDSM-5 opioid-use disordersLongitudinal studyBiological effectsHIV continuumMonth 6Immune responseDifferential biological effectsMOUDHIVSystems biology approachInfectionTreatmentDSM-5DisordersPersonsBiology approachMedicationsBuprenorphineMethadone